- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO's New Strategy to Define 'Value' in Cancer Care
The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care.
The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care.
The organization is currently developing a working definition of value that is specific to oncology, and their Value in Cancer Care Task Force is working on an algorithm that will help oncologists determine the value of different cancer treatments. Within this framework, value will be defined by clinical benefit, toxicity, and cost.
The recent ASCO State of Cancer Care in America: 2014 report makes it clear that the United States cannot sustain the continually rising cost of cancer care, said Lowell Schnipper, MD, chair of Value in Cancer Care Task Force.
It is projected that the annual cost will increase to $173 billion by 2020, which is an increase of 40% from 2010, he told to Medscape Medical News. At the same time, the demand for cancer care services is growing significantly, in large part because of the aging population, and it is estimated that the number of new cancer cases in United States will increase by 45% by 2030.
Read the full story here: http://bit.ly/1j5Vh9k
Source: Medscape
Breast Cancer Outcomes Improved in States With Medicaid Expansion
October 24th 2024Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
